Regression of aggressive laryngeal papillomatosis with 13-cis-retinoic acid (accutane).
Laryngeal papillomatosis often involves a relentless growth of papillomas on the vocal cords, requiring repeated excisions to maintain an adequate airway. Because of its antiproliferative effects on epithelial tissues, 13-cis-retinoic acid (0.5-2.0 mg/kd/day p.o.) was used in five patients whose disease was poorly controlled by laser beam surgery. Control of disease for 24+, 5+, and 12 months has been achieved in three of the patients, with two complete and one partial responses. Side effects of treatment were mild and rapidly reversible, following a 25-50% reduction in drug dose.
Alberts
D S
DS
Coulthard
S W
SW
Meyskens
F L
FL
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015474:Isotretinoin; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D010212:Papilloma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014212:Tretinoin; D015474:Isotretinoin